Company profile

Theratechnologies

Privately held: no public share price

Assets

(2 total)

2Total Assets

2Approved

0Phase 3 / Filed

0Phase 1–2 / Early

1Diseases

Showing 2 of 2 assets

		Target & Modality
Ibalizumab(Trogarzo)	Approved	CD4 receptorMonoclonal antibody	HIV
Tesamorelin(Egrifta WR)	Approved	Growth hormone-releasing hormone (GHRH) receptorPeptide	HIV

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

(3)

25 Sept25
Theratechnologies announces the completion of the acquisition by Future Pak
Theratechnologies annonce la réalisation de l’acquisition par Future Pak
Theratechnologiestranslated

view 2 more stories

Theratechnologies Announces Completion of Acquisition by Future Pak
GlobeNewswire
16 Sept25
Theratechnologies receives final court approval of the proposed arrangement plan for its acquisition by Future Pak
Theratechnologies reçoit l’approbation définitive du tribunal relativement au plan d’arrangement proposé visant son acquisition par Future Pak
Theratechnologiestranslated

Research

Research includes the full announcement history and source-linked company mentions; public profiles show up to three recent announcements.

Research

Research includes material Form 8-K and 6-K disclosures where they are available for this company.